1. Home
  2. CAAS vs ENTX Comparison

CAAS vs ENTX Comparison

Compare CAAS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAAS

China Automotive Systems Inc.

HOLD

Current Price

$4.70

Market Cap

134.9M

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.89

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAAS
ENTX
Founded
N/A
2010
Country
China
Israel
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.9M
147.4M
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
CAAS
ENTX
Price
$4.70
$2.89
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
26.0K
3.6M
Earning Date
04-22-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.22
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.97
$13.05
Revenue Growth
N/A
N/A
52 Week Low
$4.00
$0.91
52 Week High
$5.15
$4.20

Technical Indicators

Market Signals
Indicator
CAAS
ENTX
Relative Strength Index (RSI) 59.99 57.95
Support Level $4.38 $1.10
Resistance Level $4.91 $3.22
Average True Range (ATR) 0.21 0.32
MACD 0.03 -0.05
Stochastic Oscillator 53.09 13.81

Price Performance

Historical Comparison
CAAS
ENTX

About CAAS China Automotive Systems Inc.

China Automotive Systems Inc is a holding company. The firm, through its subsidiary, is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series of power steering models, including rack and pinion power steering, integral power steering, electronic power steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: